Cancer development is driven by the accumulation of genetic and epigenetic alterations that disrupt normal cellular regulation.

Although protein-coding genes have traditionally received substantial attention in cancer research, non-coding RNAs have emerged as important regulators of malignant transformation.

Among these molecules, microRNAs have attracted considerable interest.

MicroRNAs are short RNA molecules, generally approximately 20–24 nucleotides in length, that regulate gene expression by interacting with target messenger RNAs.

A single microRNA can regulate numerous target genes, while individual genes can be influenced by multiple microRNAs.

This complex regulatory organization allows microRNAs to influence entire biological pathways rather than isolated molecular targets.

Changes in microRNA expression can therefore have substantial consequences for cellular behavior.

In cancer, microRNA dysregulation can promote uncontrolled proliferation, resistance to apoptosis, angiogenesis, invasion, metastasis, and immune evasion.

MicroRNAs are also increasingly recognized as important regulators of therapeutic response.

Cancer cells can develop resistance to anticancer treatments through multiple mechanisms.

MicroRNAs can influence many of these mechanisms simultaneously, making them important components of the molecular network underlying therapeutic resistance.

Understanding the role of microRNAs in cancer development and treatment resistance may therefore provide opportunities for biomarker discovery and development of novel therapeutic strategies.

Biogenesis of MicroRNAs

MicroRNA production is a multistep process.

MicroRNA genes are generally transcribed by RNA polymerase II, producing primary microRNA transcripts known as pri-miRNAs.

These transcripts undergo processing within the nucleus to produce precursor hairpin structures.

The precursor molecules are transported to the cytoplasm and further processed into mature microRNAs.

The mature microRNA is incorporated into the RNA-induced silencing complex.

The microRNA guides this complex toward complementary sequences within target messenger RNAs.

Depending on the degree of complementarity and cellular context, the target messenger RNA may undergo degradation or translational repression.

Disruption of microRNA biogenesis can itself contribute to cancer.

Alterations in proteins involved in microRNA processing can modify global microRNA expression and influence malignant behavior.

MicroRNAs as Oncogenic Regulators

MicroRNAs that promote malignant characteristics are often described as oncogenic microRNAs or oncomiRs.

These molecules can suppress tumor-suppressor genes and thereby promote cancer development.

For example, increased expression of specific microRNAs may reduce expression of proteins involved in apoptosis or cell-cycle regulation.

This can provide cancer cells with increased survival and proliferative capacity.

Oncogenic microRNAs may also activate signaling pathways indirectly by suppressing negative regulators of growth signaling.

Tumor-Suppressive MicroRNAs

Other microRNAs function as tumor suppressors.

Their normal activity can inhibit proliferation, promote apoptosis, and maintain cellular differentiation.

Loss or reduced expression of these microRNAs can remove important restraints on tumor development.

Tumor-suppressive microRNAs may target oncogenes, growth-factor receptors, transcription factors, or signaling proteins.

Restoring their activity represents a potential therapeutic strategy.

MicroRNAs and Cancer Cell Proliferation

Uncontrolled proliferation is a fundamental characteristic of cancer.

MicroRNAs can regulate cell-cycle proteins, cyclins, cyclin-dependent kinases, transcription factors, and growth signaling pathways.

Abnormal microRNA expression can therefore alter progression through the cell cycle.

Some oncogenic microRNAs suppress cell-cycle inhibitors and facilitate continued proliferation.

Conversely, tumor-suppressive microRNAs can inhibit proliferation by targeting proteins involved in growth signaling.

MicroRNAs and Apoptosis

Cancer cells frequently acquire resistance to programmed cell death.

MicroRNAs can regulate components of both intrinsic and extrinsic apoptotic pathways.

They can influence BCL-2 family proteins, caspases, p53-associated pathways, and survival signaling.

An increase in anti-apoptotic microRNA activity can allow malignant cells to survive cellular stress and anticancer treatment.

Reduced expression of pro-apoptotic microRNAs can have a similar effect.

MicroRNAs and the PI3K–AKT–mTOR Pathway

The PI3K–AKT–mTOR pathway plays a central role in cancer-cell growth and survival.

MicroRNAs can regulate several components of this pathway directly or indirectly.

Dysregulated microRNAs may enhance pathway activation by suppressing pathway inhibitors.

Increased PI3K–AKT–mTOR signaling can promote proliferation, metabolic adaptation, and resistance to apoptosis.

Consequently, interactions between microRNAs and this pathway are important in cancer progression.

MicroRNAs and RAS–RAF–MEK–ERK Signaling

The RAS–RAF–MEK–ERK pathway regulates proliferation and differentiation.

MicroRNAs can influence this pathway by targeting receptors, signaling intermediates, and regulatory proteins.

Aberrant microRNA expression can therefore contribute to persistent MAPK signaling.

This interaction may influence both tumor growth and treatment response.

MicroRNAs and Wnt–β-Catenin Signaling

Wnt–β-catenin signaling contributes to cancer-cell proliferation, stemness, invasion, and metastasis.

MicroRNAs can regulate components of the Wnt pathway.

Changes in microRNA expression may increase β-catenin signaling and promote malignant phenotypes.

The interaction between microRNAs and Wnt signaling is particularly relevant to tumor-cell plasticity and cancer stem-cell characteristics.

MicroRNAs and Epithelial-to-Mesenchymal Transition

Epithelial-to-mesenchymal transition is associated with changes in cell adhesion, migration, and invasion.

MicroRNAs can regulate transcription factors involved in this process.

Certain microRNAs suppress epithelial-to-mesenchymal transition, whereas others promote it.

Alterations in these regulatory networks can increase tumor-cell migration and metastatic potential.

MicroRNAs and Tumor Invasion

Invasion requires cancer cells to modify adhesion, cytoskeletal organization, and extracellular matrix interactions.

MicroRNAs can regulate matrix metalloproteinases, adhesion molecules, cytoskeletal regulators, and signaling pathways.

Through these mechanisms, microRNAs can influence the invasive behavior of malignant cells.

MicroRNAs and Metastasis

Metastatic progression requires cancer cells to leave the primary tumor, enter the circulation, survive during transport, reach distant tissues, and establish secondary lesions.

MicroRNAs participate in several of these processes.

They can influence angiogenesis, epithelial-to-mesenchymal transition, immune interactions, cellular migration, and adaptation to distant tissue environments.

Some circulating microRNAs may also reflect metastatic disease activity.

MicroRNAs and Cancer Stem Cells

Cancer stem-cell-like populations can contribute to tumor initiation, recurrence, metastasis, and treatment resistance.

MicroRNAs influence pathways involved in self-renewal and cellular differentiation.

Wnt, Notch, Hedgehog, and other stem-cell-associated pathways can be regulated by microRNAs.

Altered microRNA expression may therefore contribute to maintenance of stem-like cancer-cell populations.

MicroRNAs and Angiogenesis

Tumors require blood vessels to support sustained growth.

MicroRNAs can regulate angiogenic signaling by influencing vascular endothelial growth factor and related pathways.

Some microRNAs promote angiogenesis, whereas others suppress new blood-vessel formation.

The balance between these molecules can influence tumor vascularization.

MicroRNAs and the Tumor Microenvironment

Cancer cells interact with fibroblasts, immune cells, endothelial cells, and extracellular matrix components.

MicroRNAs can participate in communication between tumor cells and surrounding cells.

Extracellular vesicles can transport microRNAs between different cell populations.

This intercellular transfer can modify the behavior of stromal and immune cells.

Such communication may promote tumor growth and contribute to therapeutic resistance.

MicroRNAs and Chemotherapy Resistance

Chemotherapy resistance is a major obstacle in cancer treatment.

MicroRNAs can influence drug sensitivity through multiple mechanisms.

They may regulate:

• Drug transport;
• Drug metabolism;
• DNA repair;
• Apoptosis;
• Cell-cycle progression;
• Oxidative stress;
• Cancer stem-cell characteristics; and
• Survival signaling.

Changes in microRNA expression can therefore make cancer cells more or less sensitive to chemotherapy.

MicroRNAs and Drug Efflux

Some cancer cells develop increased activity of ATP-binding cassette transporters.

These proteins can transport anticancer drugs out of cells, reducing intracellular drug concentrations.

MicroRNAs can regulate expression of drug-efflux proteins.

Altered microRNA activity may therefore contribute to multidrug resistance.

MicroRNAs and DNA Repair

Many anticancer treatments produce DNA damage.

Cancer cells can survive these treatments by increasing DNA repair capacity.

MicroRNAs can regulate genes involved in DNA damage recognition and repair.

Changes in these microRNAs can alter the effectiveness of DNA-damaging chemotherapy and radiotherapy.

MicroRNAs and Radiotherapy Resistance

Radiotherapy induces DNA damage and oxidative stress.

The response of tumor cells depends on DNA repair, apoptosis, cell-cycle checkpoints, and cellular stress pathways.

MicroRNAs can regulate several of these mechanisms.

Certain microRNA expression patterns have therefore been associated with increased or decreased radiosensitivity.

MicroRNAs and Targeted Therapy Resistance

Targeted therapies are designed to inhibit specific molecular abnormalities.

Cancer cells can nevertheless develop resistance through pathway reactivation, alternative signaling, mutations, or phenotypic adaptation.

MicroRNAs can regulate multiple components of these signaling networks.

They may therefore contribute to resistance even when the original therapeutic target remains inhibited.

MicroRNAs and Immunotherapy Resistance

The tumor immune microenvironment strongly influences the response to immunotherapy.

MicroRNAs can regulate immune-cell function, inflammatory signaling, antigen presentation, and immune-checkpoint pathways.

Altered microRNA expression may contribute to an immunosuppressive tumor environment.

Consequently, microRNAs are being investigated as potential predictors of immunotherapy response.

MicroRNAs as Circulating Biomarkers

MicroRNAs can be detected in blood and other biological fluids.

Their relative stability in circulation has made them attractive biomarker candidates.

Circulating microRNA profiles may differ between healthy individuals and patients with cancer.

They may potentially provide information about:

• Disease presence;
• Tumor type;
• Disease stage;
• Metastatic progression;
• Treatment response; and
• Recurrence.

However, substantial biological and technical variability remains a challenge.

Diagnostic Potential of MicroRNAs

MicroRNA signatures may help distinguish malignant from non-malignant tissues.

Because cancer-associated changes can occur before extensive clinical manifestations, microRNAs may have potential for early detection.

However, many microRNAs are involved in multiple biological processes.

Therefore, combinations of microRNAs may provide greater specificity than individual molecules.

Prognostic Potential

MicroRNA expression patterns can also provide prognostic information.

Certain expression profiles have been associated with aggressive disease, metastatic potential, recurrence, or reduced survival.

Prognostic microRNA signatures could potentially help identify patients requiring closer monitoring or more intensive treatment.

Large independent studies are needed to validate such signatures.

MicroRNAs and Precision Oncology

Cancer is molecularly heterogeneous.

Patients with the same histological cancer type may have substantially different molecular characteristics.

MicroRNA profiling may provide additional information about tumor biology.

Integration of microRNA expression with genomic, transcriptomic, proteomic, and clinical data could improve patient stratification.

This approach may support more individualized treatment decisions.

Therapeutic Modulation of MicroRNAs

The therapeutic manipulation of microRNAs can involve two broad strategies.

The first is restoration of tumor-suppressive microRNAs that are lost during cancer development.

The second is inhibition of oncogenic microRNAs that become abnormally elevated.

MicroRNA mimics can be designed to reproduce the function of tumor-suppressive microRNAs.

Antisense oligonucleotides or related inhibitors can be used to reduce activity of oncogenic microRNAs.

MicroRNA Mimics

MicroRNA mimics are synthetic molecules designed to reproduce the biological activity of endogenous microRNAs.

When delivered to cancer cells, they may restore suppression of oncogenic targets.

This approach has attracted interest because a single microRNA can regulate multiple genes within a disease-associated pathway.

However, broad target regulation can also create unwanted effects.

Anti-MicroRNA Strategies

Anti-microRNA molecules are designed to bind and inhibit specific microRNAs.

They may be useful when an oncogenic microRNA is overexpressed.

By blocking the microRNA, expression of its target tumor-suppressor genes may be restored.

The specificity and delivery of these molecules remain important challenges.

MicroRNA Delivery Systems

Effective delivery is essential for microRNA-based therapy.

Potential delivery approaches include:

• Lipid nanoparticles;
• Polymer-based nanoparticles;
• Viral vectors;
• Extracellular vesicles; and
• Targeted delivery systems.

An effective delivery system should protect the therapeutic molecule, facilitate cellular uptake, and minimize off-target effects.

Review Design

The present article was prepared as a narrative review examining the molecular role of microRNAs in cancer development and therapeutic resistance.

Literature Search

Relevant scientific literature was evaluated from biomedical databases and peer-reviewed scientific journals.

Search terms included combinations of:

“microRNA,” “miRNA,” “cancer development,” “oncogenesis,” “tumor suppressor microRNA,” “oncomiR,” “chemotherapy resistance,” “radiotherapy resistance,” “targeted therapy resistance,” “immunotherapy resistance,” “microRNA biomarkers,” “microRNA therapeutics,” “epithelial mesenchymal transition,” and “cancer stem cells.”

Inclusion Criteria

Publications were considered relevant when they investigated:

• MicroRNA biology in cancer;
• MicroRNA regulation of oncogenic pathways;
• MicroRNA-associated tumor progression;
• Therapeutic resistance;
• Circulating microRNA biomarkers; or
• MicroRNA-based therapeutic approaches.

Exclusion Criteria

Publications without substantial relevance to cancer-associated microRNA mechanisms or therapeutic response were excluded from the primary synthesis.

Data Synthesis

The available evidence was organized according to microRNA biogenesis, oncogenic and tumor-suppressive functions, cancer progression, treatment resistance, biomarker potential, and therapeutic applications.

Results

The reviewed evidence demonstrates that microRNAs participate in multiple stages of cancer development.

Dysregulated microRNAs can influence cellular proliferation, apoptosis, invasion, metastasis, angiogenesis, cancer stem-cell maintenance, and immune regulation.

MicroRNAs interact with major oncogenic pathways, including PI3K–AKT–mTOR, RAS–RAF–MEK–ERK, Wnt–β-catenin, JAK–STAT, and transforming growth factor-β signaling.

Evidence also indicates that microRNAs can contribute to resistance against chemotherapy, radiotherapy, targeted therapy, and immunotherapy.

These effects are mediated through regulation of apoptosis, DNA repair, drug transport, cellular metabolism, epithelial-to-mesenchymal transition, and survival pathways.

Circulating microRNAs have potential as minimally invasive biomarkers.

However, differences in patient populations, sample collection, RNA extraction, normalization methods, and analytical platforms remain significant barriers to clinical standardization.

MicroRNAs represent a highly complex regulatory layer within cancer biology.

Their ability to regulate multiple target genes means that changes in a single microRNA can influence several biological processes simultaneously.

This characteristic helps explain their involvement in cancer development.

Oncogenic microRNAs can suppress tumor-suppressor genes, whereas tumor-suppressive microRNAs can restrain oncogenic pathways.

The balance between these two functional groups can strongly influence tumor behavior.

One of the most important features of microRNA biology is their interaction with major signaling networks.

Cancer cells rarely depend on a single molecular pathway.

Instead, several pathways cooperate to maintain proliferation and survival.

MicroRNAs can simultaneously influence multiple components of these networks.

This may explain why altered microRNA expression can produce broad phenotypic effects.

The same property, however, creates challenges for therapeutic development.

Because one microRNA can regulate numerous genes, therapeutic manipulation may produce unintended effects in normal tissues.

Therapeutic resistance is another major area in which microRNAs have gained importance.

Cancer cells can adapt to treatment through changes in apoptosis, DNA repair, drug transport, metabolism, and cellular phenotype.

MicroRNAs can regulate several of these mechanisms.

For example, increased expression of certain microRNAs can suppress pro-apoptotic proteins, allowing malignant cells to survive chemotherapy.

Other microRNAs may regulate DNA repair proteins and thereby influence radiation sensitivity.

MicroRNAs can also promote epithelial-to-mesenchymal transition and cancer stem-cell characteristics.

These changes can produce populations of cells with increased survival capacity and reduced treatment sensitivity.

The tumor microenvironment further complicates microRNA regulation.

MicroRNAs can be transported between cancer cells and stromal cells through extracellular vesicles.

This creates a mechanism for communication that can modify the behavior of neighboring cells.

Such interactions may contribute to tumor progression and resistance.

Circulating microRNAs are particularly attractive as biomarkers because they can potentially be detected through minimally invasive blood sampling.

Their stability in circulation provides an advantage over some other RNA molecules.

However, the clinical translation of microRNA biomarkers requires standardized methods.

Differences in blood collection, RNA extraction, normalization, and detection platforms can significantly influence measured expression levels.

Future studies should therefore prioritize reproducibility and validation across independent populations.

Therapeutic Perspectives

MicroRNA-based therapy represents an emerging area of precision oncology.

Restoration of tumor-suppressive microRNAs could potentially inhibit multiple oncogenic pathways simultaneously.

Conversely, inhibition of oncogenic microRNAs may restore expression of several tumor-suppressor genes.

Combination approaches may be particularly promising.

For example, microRNA-based treatment could potentially be combined with chemotherapy, targeted therapy, radiotherapy, or immunotherapy.

However, successful clinical application depends heavily on effective delivery.

MicroRNA molecules can be unstable and may undergo rapid clearance.

Nanoparticle and extracellular-vesicle-based delivery systems may improve stability and cellular uptake.

Tumor-specific targeting could further reduce effects on normal tissues.

Another potential approach is personalized microRNA therapy.

Molecular profiling could identify which microRNAs are dysregulated in an individual tumor.

Treatment could then be selected according to the patient's specific molecular characteristics.

Future Perspectives

Future research should investigate microRNA function at single-cell resolution.

Single-cell approaches can determine whether particular microRNAs are expressed in malignant cells, immune cells, fibroblasts, or endothelial cells.

This distinction is important because the same microRNA may have different effects in different cell types.

Spatial molecular technologies may further clarify how microRNAs influence interactions within the tumor microenvironment.

Artificial intelligence may also help identify complex microRNA signatures associated with treatment response.

Integration of microRNA profiles with genomic and proteomic data could improve prediction of therapeutic resistance.

Future clinical trials should use standardized methods for microRNA measurement and include large, independent patient populations.

More research is also needed to determine whether microRNA-based interventions can produce durable clinical responses without unacceptable toxicity.

MicroRNAs are important regulators of cancer development and therapeutic resistance.

Their ability to control multiple target genes enables them to influence proliferation, apoptosis, invasion, metastasis, angiogenesis, metabolism, cancer stem-cell behavior, and immune regulation.

Dysregulated microRNAs can function as oncogenic molecules or tumor suppressors depending on their targets and cellular context.

MicroRNAs also contribute to resistance against chemotherapy, radiotherapy, targeted therapies, and immunotherapy by regulating apoptosis, DNA repair, drug transport, cellular plasticity, and survival signaling.

Circulating microRNAs have considerable potential as minimally invasive diagnostic, prognostic, and predictive biomarkers.

MicroRNA mimics and anti-microRNA approaches represent promising therapeutic strategies, although effective delivery, specificity, off-target effects, and biological variability remain important challenges.

Future research combining microRNA profiling with multi-omics analysis, single-cell technologies, artificial intelligence, and precision medicine approaches may improve understanding of cancer biology and facilitate development of individualized therapeutic strategies.

1. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
3. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews Genetics. 2004;5:522–531.
4. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature Reviews Cancer. 2006;6:857–866.
5. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer. 2006;6:259–269.
6. Iorio MV, Croce CM. MicroRNA involvement in human cancer. Carcinogenesis. 2012;33:1126–1133.
7. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annual Review of Medicine. 2009;60:167–179.
8. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends in Molecular Medicine. 2014;20:460–469.
9. Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduction and Targeted Therapy. 2016;1:15004.
10. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Reviews Drug Discovery. 2017;16:203–222.
11. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clinical Pharmacology & Therapeutics. 2013;93:98–104.
12. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nature Reviews Clinical Oncology. 2014;11:145–156.
13. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences. 2008;105:10513–10518.
14. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172–1187.
15. Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduction and Targeted Therapy. 2016;1:15004.
16. Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK. miRNA deregulation in cancer cells and its therapeutic implications. Clinical Cancer Research. 2016;22:624–632.
17. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nature Reviews Cancer. 2015;15:321–333.
18. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annual Review of Pathology. 2014;9:287–314.
19. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Research. 2011;39:7223–7233.
20. Ha M, Kim VN. Regulation of microRNA biogenesis. Nature Reviews Molecular Cell Biology. 2014;15:509–524.